COBRA-1
Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antithrombotics
- Mechanism of Action Apoptosis stimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 May 2000 New profile
- 23 May 2000 Preclinical development for Cancer in USA (Unknown route)